Key bank earnings and economic data have reinvigorated the U.S stock market today. The Consumer Price Index and initial jobless claims data were better than expected, paving the way for a rally after two days of losses. Three stocks stood out today, namely Keryx Biopharmaceuticals (NASDAQ:KERX), Transition Therapeutics Inc (USA) (NASDAQ:TTHI) and Tata Motors Limited (ADR) (NYSE:TTM). Let’s take a look at why they are surging and whether the smart money saw it coming.
Wall Street Bull
Indian car maker Tata Motors Limited (ADR) (NYSE:TTM) has made headlines today, as investors expect the new round of models introduced by the company’s luxury division, Jaguar Land Rover, will boost sales. Analysts at Ambit Capital believe the introduction of new models, notably the Jaguar XE and Discovery Sport, will result in sales of more than 500,000 vehicles in the 12 months through March, amid strong demand in Europe and the United States. In September, sales were up by 22% to 10,394 cars, with the introduction of the Jaguar XE as the main catalyst. Could this trigger a comeback for the stock? Shares have been on a strong downtrend so far this year, but have managed to stage a small rally since the start of the month, which has continued today with gains of 7.86%.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Ken Fisher is a big fan of Tata Motors Limited (ADR) (NYSE:TTM), holding the largest stake among the funds we follow. In its latest 13F filing, Fisher Asset Management reported ownership of 8.17 million shares, up by 18% between April 1 and June 30. Cliff Asness is also optimistic about the prospects of the Indian car maker, lifting his position to 4.36 million shares. In gerenal, however, Tata Motors is not very popular among the hedge funds we track, as their combined positions account for just 3.3% of the company’s common stock. During the second quarter, the number of funds invested in the car maker fell to 20 from 24, while the value of their holdings fell by 19% to $580 million.
Why do we pay attention to hedge fund sentiment? Most investors ignore hedge funds’ moves because as a group their average net returns trailed the market since 2008 by a large margin. Unfortunately, most investors don’t realize that hedge funds are hedged and they also charge an arm and a leg, so they are likely to underperform the market in a bull market. We ignore their short positions and by imitating hedge funds’ stock picks independently, we don’t have to pay them a dime. Our research has shown that hedge funds’ long stock picks generate strong risk-adjusted returns. For instance the 15 most popular small-cap stocks outperformed the S&P 500 Index by an average of 95 basis points per month in our back-tests spanning the 1999-2012 period. We have been tracking the performance of these stocks in real-time since the end of August 2012. After all, things change and we need to verify that back-test results aren’t just a statistical fluke. We weren’t proven wrong. These 15 stocks managed to return 102% over the last 37 months and outperformed the S&P 500 Index by 53 percentage points (see the details here).
On the next page we will discuss the two biotech stocks that have gotten investors excited today.
Keryx Biopharmaceuticals (NASDAQ:KERX)’ shares bounced today after the company announced an agreement to raise $125 million from Seth Klarman‘s Baupost Group in exchange for Convertible Senior Notes due 2020. In addition, the company has agreed to extend its board of directors by one seat and allow Baupost to appoint both a director and an observer by the end of 2015. The company has also announced a cost-cutting program,which will aim to reduce expenses by as much as $92 million in 2016. During the first hour of trading, shares of Keryx jumped by as much as 13.5% and after a minor pull back, are trading up by 7.75% in afternoon trading.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
The elite funds tracked by Insider Monkey have control over roughly one-third of Keryx Biopharmaceuticals (NASDAQ:KERX)’s outstanding stock, yet their interest seems to be fading. During the second quarter, the number of funds invested in the company fell to 18 from 23, while their combined holdings were valued at $325 million, down by 29%. Although the stock has been in a downtrend, Seth Klarman kept buying shares of Keryx, boosting his stake by 16% during the second quarter. According to its latest 13F filing, Baupost Group holds nearly 25.8 million shares. Israel Englander is also betting big on the stock, having tripled his stake during the quarter. His fund, Millennium Management, holds 641,448 shares of Keryx.
Investors have greeted news related to Transition Therapeutics Inc (USA) (NASDAQ:TTHI)’s results with ELND005, the company’s experimental drug designed to reduce agitation and aggression in Alzheimer’s patients, with enthusiasm. Although the company announced in June that the drug had no effect among a large sample of Alzheimer’s patients, it has identified a sub-group that reacted positively to the drug. Transition Therapeutics intends to use these results as a basis for late-stage trial discussions with the U.S. Food and Drug Administration. The stock is currently trading at $2.17, 12.44% higher than yesterday’s closing price.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Elite funds are avoiding Transition Therapeutics Inc (USA) (NASDAQ:TTHI) for the most part, and those few that were invested in the company reduced their exposure throughout the second quarter. Only six funds in our database reported ownership of the stock as of the end of June, down from seven as of the end of the first quarter, while the value of their combined stakes plummeted by 83% to just $1.88 million. Hedge funds’ holdings account for an insignificant 2.3% of Transition Therapeutics’ common stock. Hal Mintz, the manager of Sabby Capital, is bullish on this stock, increasing his stake by 13% during the second quarter to 302,837 shares. Jim Simons‘ mathematical models seem to point in the opposite direction, however, as Renaissance Technologies reduced its holding by 6% to 179,300 shares.
Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!
It’s the revolution reshaping every industry on the planet.
From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.
Here’s why this is the prime moment to jump on the AI bandwagon:
Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.
Imagine every sector, from healthcare to finance, infused with superhuman intelligence.
We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.
This isn’t a maybe – it’s an inevitability.
Early investors will be the ones positioned to ride the wave of this technological tsunami.
Ground Floor Opportunity: Remember the early days of the internet?
Those who saw the potential of tech giants back then are sitting pretty today.
AI is at a similar inflection point.
We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.
This is your chance to get in before the rockets take off!
Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.
AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.
The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.
As an investor, you want to be on the side of the winners, and AI is the winning ticket.
The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.
From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.
This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.
By investing in AI, you’re essentially backing the future.
The future is powered by artificial intelligence, and the time to invest is NOW.
Don’t be a spectator in this technological revolution.
Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.
This isn’t just about making money – it’s about being part of the future.
So, buckle up and get ready for the ride of your investment life!
Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)
The AI revolution is upon us, and savvy investors stand to make a fortune.
But with so many choices, how do you find the hidden gem – the company poised for explosive growth?
That’s where our expertise comes in.
We’ve got the answer, but there’s a twist…
Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.
That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!
Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.
This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.
It’s like having a race car on a go-kart track.
They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.
Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.
We want to make sure none of our valued readers miss out on this groundbreaking opportunity!
That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.
For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!
Here’s why this is a deal you can’t afford to pass up:
Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Reports: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.
Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.
Here’s what to do next:
Head over to our website and subscribe to our Premium Readership Newsletter for just $29.
Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.
Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!
I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.
We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…
Should I put my money in Artificial Intelligence?
Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.
Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…
But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.
That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…
And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.
He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.